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Abstract
Stromal cells such as myofibroblasts influence tumor progression. The mechanisms are unclear but may involve effects on
both tumor cells and recruitment of bone marrow-derived mesenchymal stromal cells (MSCs) which then colonize tumors.
Using iTRAQ and LC-MS/MS we identified the adipokine, chemerin, as overexpressed in esophageal squamous cancer
associated myofibroblasts (CAMs) compared with adjacent tissue myofibroblasts (ATMs). The chemerin receptor, ChemR23,
is expressed by MSCs. Conditioned media (CM) from CAMs significantly increased MSC cell migration compared to ATM-CM;
the action of CAM-CM was significantly reduced by chemerin-neutralising antibody, pretreatment of CAMs with chemerin
siRNA, pretreatment of MSCs with ChemR23 siRNA, and by a ChemR23 receptor antagonist, CCX832. Stimulation of MSCs by
chemerin increased phosphorylation of p42/44, p38 and JNK-II kinases and inhibitors of these kinases and PKC reversed
chemerin-stimulated MSC migration. Chemerin stimulation of MSCs also induced expression and secretion of macrophage
inhibitory factor (MIF) that tended to restrict migratory responses to low concentrations of chemerin but not higher
concentrations. In a xenograft model consisting of OE21 esophageal cancer cells and CAMs, homing of MSCs administered
i.v. was inhibited by CCX832. Thus, chemerin secreted from esophageal cancer myofibroblasts is a potential
chemoattractant for MSCs and its inhibition may delay tumor progression.
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Introduction
The importance of the tumor microenvironment in determining
cancer cell growth and spread is now well recognised [1]. Stromal
cell types that contribute to the microenvironment include
inflammatory and immune cells, endothelial cells, pericytes and
fibroblast cell lineages [2]. In the case of the latter a growing body
of evidence indicates that cancer-associated fibroblasts (CAFs), of
which myofibroblasts are a prominent subtype, differ from their
counterparts in normal tissue [3,4,5]. There is also a growing
appreciation that bone marrow derived mesenchymal stromal
(stem) cells (MSCs) can influence cancer progression by migration
to tumor sites where they may differentiate into a variety of cell
types including myofibroblasts [6,7]; they may also be useful as
vehicles to provide targeted anticancer therapy [8]. Although there
is evidence for chemokine involvement in MSC recruitment the
mechanisms remain poorly understood [9,10].
Esophageal cancer is considered to account for nearly half a
million deaths a year worldwide. Adenocarcinoma, associated with
reflux and obesity, arises on a background of Barrett’s esophagus
and is increasing in incidence in Western societies; esophageal
squamous cell carcinoma (ESCC) is associated with smoking,
alcohol intake and poor diet and is of high incidence in developing
countries [11]. There is a growing appreciation of the role of
CAFs/myofibroblasts in ESCC particularly in promoting cancer
invasion and angiogenesis although in general these remain poorly
understood [12,13].
Chemerin (tazarotene induced gene 2, TIG2; retinoic acid
receptor responder 2, RARRES2) is an 18 kDa chemokine-like
protein that acts at ChemR23 (chemokine-like receptor 1,
CMKLR1) [14,15]. It is secreted as an inactive precursor that is
activated by a variety of extracellular proteases which remove a C-
terminal hexapeptide to liberate a 157 amino acid active form; it is
expressed in adipocytes, liver and placenta and has roles in
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adipogenesis and leukocyte chemotaxis including the recruitment
of dendritic and natural killer (NK) cells to sites of inflammation or
cancer [16,17,18,19]. In the present study we identified increased
expression of chemerin in ESCC cancer-associated myofibrobro-
blasts (CAMs) compared with adjacent tissue myofibroblasts
(ATMs), and found expression of its cognate receptor ChemR23
by MSCs. We therefore hypothesised that chemerin acts as an




Myofibroblasts were generated from tumors and adjacent tissue
of patients with ESCC using previously described methods (Table
S1 in File S1) [20,21], and were used between passages 3 and 10.
This work was approved by the Ethics Committee of the
University of Szeged, Hungary and all subjects gave informed
consent. ESCC cells (OE21) and human umbilical vein endothelial
cells (HUVEC) were obtained from American Type Culture
Collection (Manassas, VA). Human bone marrow derived
mesenchymal stem cells were used at passages 3-12 in their
undifferentiated state; up to passage 12 they exhibited adipocyte,
osteocyte and chondrocyte differentiation in adipocyte, osteocyte
and chondrocyte differentiation media (Lonza, Cambridge, UK);
the cells were CD105, CD166, CD29, CD44, a-SMA and
vimentin positive and were CD14, CD34, CD45, cytokeratin
and desmin negative.
Cell Culture
Myofibroblasts were cultured as previously described [20].
MSCs were maintained in an undifferentiated state in MSCGM
(Lonza) containing basal medium and MSC growth supplements.
Cells were maintained at 37uC in 5% v/v CO2; HUVECs were
maintained in EGM medium and were used at passages 5 to 9;
OE21 cells were cultured in RPMI-1640 supplemented with 10%
v/v FBS, 1% v/v penicillin-streptomycin, 2% v/v L-glutamine.
Conditioned media
Myofibroblasts (1.56106 cells) were plated in T-75 falcon flasks
and maintained at 37uC in 5% v/v CO2 for 24 h in full media
(FM). Cultures were then washed 3 times with sterile PBS and
incubated in 15 ml serum free (SF) media for 24 h. Conditioned
media (CM) were collected, centrifuged (7 min, 8006g, 4uC) and
aliquots were stored at 280uC until further use.
Immunocytochemistry
Cells were paraformaldehyde(PFA)-fixed (4% w/v), permeabi-
lised with 0.2% Triton X-100 in PBS (PBS-T) for 30 min and
processed for immunocytochemistry as previously described [22]
using primary antibodies to CD105, CD34, CD29 (Ancell
Corporation, Bayport, MN), a-SMA, vimentin, desmin, pancyto-
keratin (Fitzgerald, NJ), ChemR23 (Millipore, MA,) or GPR1
(Abcam, Cambridge, UK) followed by incubation with the
appropriate fluorescein or Texas Red labelled secondary antibod-
ies raised in donkey (Jackson Immunoresearch, Soham, UK), and
mounted with VectashieldH containing DAPI (Vector Laborato-
ries, Peterborough, UK). Slides were viewed using a Zeiss
Axioplan-2 microscope (Zeiss Vision, Welwyn Garden City,
UK). Images were captured using a JVC-3 charge-coupled device
camera at 406 magnification with KS300 software (Imaging
Associates, Bicester, Oxfordshire, UK).
Proteomic analysis
The secretome of esophageal myofibroblasts was studied after
iTRAQ labelling of proteins in media followed by LC-MS/MS as
previously described (see Methods S1) [3]. Putative chemerin
targets in MSCs were sought after SILAC labelling of cells
followed by exposure to chemerin (R&D Systems, Abindgon,
Oxfordshire, UK) for 24 h and processing of cells for LC-MS/MS
(see Methods S1) as previously described [23].
Western blotting
Media or cell extracts prepared in RIPA buffer containing
protease and phosphatase inhibitors were resolved by SDS-PAGE
electrophoresis and processed for Western blotting as previously
described [24] using antibodies to chemerin, macrophage migra-
tion inhibiting factor (MIF), matrix metalloproteinase (MMP)-2
(R&D Systems), GAPDH (Biodesign, Maine), total and phosphor-
ylated p42/44, p38 and JNK-II kinases (Cell Signaling, Massa-
chusetts).
ELISA
ELISAs for chemerin (Adipo Bioscience, CA, USA) and MIF
(R&D Systems) were applied to myofibroblast media according to
the manufacturer’s instructions.
Cell migration assays
Transwell migration assays were performed using BD inserts
(BD Bioscience, California) as previous described [25] employing
chemerin (R&D Systems), chemerin-9 (Piscataway, NJ) or
undiluted CM in the lower well. The effects were studied of
phorbol 12-myristate 13-acetate (PMA), Ro320432, SB202190,
SP600125, U0126, ISO-1 (Calbiochem, Darmstadt, Germany),
LY294002 (New England labs, Hertfordshire, UK), chemerin
neutralising antibody (MAb2325, R&D Systems), CCX-832 and
CCX826 (ChemoCentryx, Mountain View, CA) [26]. Scratch
wound migration assays were performed as previously described
[27]. Transendothelial migration assays were performed using
MSCs labelled with 1 mM PKH67 (Sigma Aldrich, Dorset, UK)
according to the manufacturer’s instructions and BD BioCoat
Matrigel Invasion Chambers (BD Bioscience) coated with a
monolayer of HUVECs 48 h previously. Migrating MSCs were
subsequently counted as fluorescent cells.
MMP-2 activity assays
MMP-2 activity in MSC media was determined by a selective
fluorescence substrate, MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-
NH2, according the manufacturer’s instructions (Merk Bioscienc-
es, Beeston, Nottingham, UK).
Chemerin, chemR23, GPR-1 and MIF knockdown
Myofibroblasts were transfected with 3 different silencing RNAs
(siRNA, Table S2 in File S1)(3 mM) for chemerin (Sigma, UK).
MSCs were treated with three different siRNAs (Table S2 in File
S1)(3 mM) for chemR23, and validated siRNAs for GPR-1 and
MIF (Invitrogen, Paisley, UK). The efficiency of knockdown was
verified by Western blotting or immunocytochemistry.
Transient transfection
Cells were transfected using Amaxa Fibroblasts Nucleofector
kits (Amaxa; Ko¨ln, Germany) and AmaxaTM Human MSC
Nucleofector kits (Amaxa; Ko¨ln, Germany) according to manu-
facturer’s instructions. Each transfection employed 2 mg of DNA
(56105 cells) and 100 ml of complete nucleofector solution.
Transfection was achieved using program U-23 (for high
Chemerin and MSC Recruitment
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e104877
transfection efficiency) by adding 500 ml of the pre-warmed culture
medium to the cuvette and transfer of samples to T-75 flasks with
20 ml of freshly prepared medium.
MSC homing to xenografts
All animal experiments were conducted after approval by the
University of Liverpool Animal Welfare Committee and were in
compliance with the U.K. Animals (Scientific Procedures) Act
1986 (PPL 40/3137).To study MSC recruitment to xenografts, 6-8
week-old immunocompromised BALB/c nu/nu mice (Charles
River, Wilmington, MA) were injected s.c. with OE21 cells (106)
alone or with CAMs (56105). Mice with tumors of comparable
size (1.0–1.2 cm diameter) subsequently received CCX832 (2 mg/
ml, 125 ml, i.v.), or vehicle, followed after 24 h by a second dose
and MSCs labelled with PKH67 (7.56105). After 24 h, tumours
were dissected, fixed in 4% PFA and processed for localisation of
fluorescent cells.
Statistics
The final results were calculated as mean 6 standard error of
means (SEM). Student t-test and ANOVA were performed on the
data as appropriate with significance at p#0.05 using Systat
Software Inc. (London, UK) unless otherwise stated.
Results
Increased chemerin expression in squamous esophageal
CAMS
Myofibroblasts identified by a-SMA expression were found in
greater numbers and exhibited disrupted morphology and
architecture in ESCC compared with adjacent tissue (Fig S1 in
File S2). Cultured myofibroblasts from these tumors and adjacent
tissue expressed a-SMA and vimentin, but not desmin or
cytokeratin; CM from CAMs stimulated growth and migration
of OE21 cells compared with ATM-CM (Figs S2, S3 in File S2).
Using iTRAQ labeling followed by LC-MS/MS to identify
potential cell signalling molecules secreted by CAMs, we found
increased chemerin abundance in CAM media compared with
ATM from all of four pairs of ESCC samples (Fig S4 in File S2;
Table S3 in File S1). Western blotting confirmed increased
chemerin in CAM compared with ATM media (Fig 1A), and
ELISA of media indicated 2.160.4 fold higher chemerin secretion
by CAMs vs ATMs. In cell extracts, Western blots showed modest
but significantly elevated chemerin in CAMs compared with their
paired ATMs (Fig S5 in File S2). A putative chemerin receptor,
ChemR23, was expressed by MSCs (see below), and chemerin
stimulated concentration-dependent migration of MSCs in two
different assays (Fig 1B). Moreover, CAM-CM stimulated MSC
migration and the response was significantly greater than to ATM-
CM (Fig 1C, left). Direct evidence for a role of chemerin as an
active component of CAM-CM was provided by the observation
that immunoneutralisation of chemerin inhibited the effect of
CAM-CM (Fig 1C, center); additionally, siRNA knockdown of
chemerin expression decreased the activity of CM subsequently
applied to MSCs in migration assays (Fig 1C, right; Fig S6 in File
S2).
ChemR23 expressed by MSCs mediates migratory
responses to chemerin
The expression in MSCs of the putative chemerin receptor,
ChemR23, has been identified by gene array [28] and we
confirmed expression of this and a second putative receptor,
GPR1 [29], by immunocytochemistry. Knockdown by siRNA of
ChemR23 (Fig 2A, left; Fig S7 in File S2) significantly inhibited
the migratory response to both chemerin (Fig 2A, center) and
CAM-CM (Fig 2A, right), while knockdown of GPR1 had little
effect. A ChemR23 antagonist, CCX832, dose-dependently
inhibited MSC migration in response to chemerin (Fig 2B, left
and center) and CAM-CM (Fig 2B, right) while an inactive
analogue, CCX826 had no effect; the inhibition of CAM-CM by
CCX832 was similar to that achieved by immunoneutralisation
(Fig 2B, right).
Chemerin stimulation of protein kinase pathways
mediates MSC migratory responses
Chemerin promptly increased phosphorylation of several
protein kinases including p42/44, p38 and JnkII kinases in MSCs
(Fig 2C, left). Inhibitors of all three kinases significantly reduced
the migratory response of MSCs to chemerin but inhibition of PI-
3-kinase using LY294002 had no effect. The PKC inhibitor
Ro320432 also inhibited migration, and the combination of
Ro320432, U0126, SP600125 and SB202190 completely inhibited
migratory responses (Fig 2C, right). Evidence that PKC activation
was upstream of MAP kinase stimulation is provided by the
observation that PMA stimulated MSC migration and this was
inhibited by U0126, SP600125 and SB202190; moreover, PMA
stimulated phosphorylation of p42/44, p38 and JnkII kinases (Fig
S8 in File S2). There was a marked reduction in phosphorylation
of p42/44, p38 and JnkII kinases after ChemR23 knockdown
using siRNA consistent with the idea that these kinases are
downstream of ChemR23 (Fig S8 in File S2).
Chemerin increases MIF expression in MSCs which
restrains migration
In order to further define putative targets of chemerin we
applied SILAC and LC-MS/MS to the identification of proteins
in cell extracts and media of MSCs treated with chemerin for 24 h.
Unexpectedly, MIF was increased in chemerin-stimulated cells
(Table S4 in File S1; Fig S9 in File S2). Western blot verified that
chemerin, as well as IGF-II used as a positive control, increased
MIF in cell extracts and media (Fig 3A, left), and using ELISA
there was approximately 10-fold higher MIF concentrations in
media after chemerin treatment. Following ChemR23 knockdown
the MIF response to chemerin was profoundly inhibited (Fig 3A,
center). In the presence of MIF, the MSC migratory response to
chemerin was inhibited by approximately 50% (Fig 3A, right). To
determine the functional significance of MIF in MSC migration
we employed the MIF antagonist ISO-1; this suppressed the effect
of MIF in inhibiting chemerin-stimulated MSC migration, and
significantly increased the migratory response of MSCs to
chemerin (Fig 3B). Similarly, MIF knockdown (Fig S10 in File
S2) increased MSC migration in response to low concentrations of
chemerin (4 ng/ml), but interestingly the response to chemerin at
higher concentrations (20 ng/ml) was not influenced by MIF
knockdown (Fig 3C).
Chemerin stimulates MSC migration across endothelial
cells and requires MMP-2
The data implicate chemerin in the recruitment of MSCs to
CAM-containing cancer microenvironments. In vivo this requires
transendothelial migration and so we examined whether chemerin
was able to stimulate MSC migration through a monolayer of
endothelial cells previously formed on Boyden chambers. MSCs
labelled with PKH67 (Fig 4A, left) were identified as migrating in
response to chemerin (Fig 4A, center) and CAM-CM (Fig 4A,
right), and the migratory response was inhibited by CCX832 but
Chemerin and MSC Recruitment
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not CCX826. Secreted proteases that might facilitate transen-
dothelial migration were then sought in the protein lists obtained
from SILAC-labelled MSCs treated with chemerin. Abundant
MMP-2 was identified in chemerin-stimulated samples (Table S5
in File S1) and Western blots (Fig 4B, left) and MMP-2 enzyme
activity assays (Fig 4B, right) confirmed increased abundance in
media in response to chemerin. In migration studies, addition of
MMP-2 stimulated MSC migration and this was significantly
reduced by a MMP-2 inhibitor (Fig 4C left). The same inhibitor
also significantly reduced MSC transendothelial migration in
response to chemerin (Fig 4C, right).
Figure 1. Chemerin exhibits increased expression in CAMs and stimulates MSCmigration. A. Representative Western analysis of chemerin
in media from ESCC CAMs and ATMs (left). Quantitative analysis by densitometry of chemerin abundance in media from ESCC CAMs and ATMs (n = 4
different pairs of myofibroblasts) (right). B. Concentration-dependent stimulation of MSC migration by chemerin in scratch wound migration assays
(left) and Boyden chamber migration assays (right)(n = 3). C. Increased migration of MSCs in Boyden chambers in response to conditioned media (CM)
from CAMs and their respective ATMs (left) (n = 4 different pairs of myofibroblasts). Stimulation of MSC migration by CAM-CM was inhibited by
chemerin neutralizing antibody (Chem.Ab; 10 mg/ml) (center). MSC migration was decreased in response to CM from CAM1 and CAM4 cells
transfected with chemerin siRNA#3 (right). Horizontal arrows, p,0.05, t- test (n = 3).
doi:10.1371/journal.pone.0104877.g001
Chemerin and MSC Recruitment
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Figure 2. ChemR23 mediates chemerin stimulation of MSC migration via PKC and MAP kinases. A, Representative images from MSCs
stained for vimentin (positive control) and chemR23 revealing knock-down (KD) after ChemR23 siRNA treatment (left). Knockdown of ChemR23, but
not GPR1, inhibited MSC migration in response to chemerin (100 ng/ml)(center) and CAM-CM (right). B, Concentration-dependent inhibition of MSC
migration in response to chemerin by the ChemR23 antagonist CCX832 (left) but not the control compound CCX826 (1 mM) (center). MSC migration
in response to CAM-CM was inhibited similarly by chemerin neutralising antibody, and CCX832, but not CCX826 (1 mM)(right). C, Representative
Western blot shows increased phosphorylation of p42/44, p38 and JNK-II kinases in MSCs treated with chemerin (100 ng/ml)(left). In Boyden chamber
assays, chemerin-stimulated MSC migration was inhibited by the JNK-II inhibitor, SP600125 (50 mM), the p42/44 inhibitor, UO126 (10 mM), p38
inhibitor SB202190 (3 mM), and the PKC inhibitor Ro320432 (2 mM) but not by PIK3 inhibitor LY294002 (50 mM) (right). Horizontal arrows, p,0.05,
ANOVA (n= 3 in each case).
doi:10.1371/journal.pone.0104877.g002
Chemerin and MSC Recruitment
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In a xenograft model, MSC homing is stimulated by
CAMs and inhibited by CCX832
On the basis of the data described above, we hypothesised that
in vivo chemerin mediates MSC homing to tumors consisting of
cancer cells and CAMs. In a xenograft model of OE21 cells in
nude mice, matched tumors of similar size (1.0–1.2 cm diameter)
generated with and without co-administration of CAMs were
studied after subsequent i.v. injection of PKH67-labelled MSCs.
Labelled cells in the xenografts were increased in tumors of OE21
and CAMs compared with OE21 cells alone (Fig 5A). Pretreat-
ment of mice with the ChemR23 antagonist CCX832 prior to
injecting MSCs significantly reduced the number of labelled cells
in the xenografts thereby demonstrating a role for chemerin in
MSC recruitment in vivo (Fig 5B).
Discussion
There is increasing evidence that MSCs migrate to tumors
where they contribute to tumor growth [6,30]. The mechanisms of
homing and migration remain incompletely understood. In this
study we provide evidence that expression of the chemokine-like
peptide, chemerin, is increased in CAMs from ESCC and acts as a
chemoattractant for MSCs via activation of the G-protein coupled
receptor ChemR23. A small molecule antagonist of ChemR23,
CCX832, inhibited the action of chemerin both in vitro and in a
xenograft model in vivo. The findings identify chemerin as a novel
CAM-derived determinant of MSC recruitment to tumors.
Previous studies have reported a number of different roles for
CAFs, CAMs and related cells in the progression and response to
therapy of a variety of cancers including prostate, breast, stomach,
lung and colon [2,31,32,33,34,35]. The CAMs used for the
present studies were derived from tumors in which myofibroblast
number, architecture and morphology were disrupted; moreover
CM from these CAMs evoked a more aggressive phenotype in
cancer cells (proliferation, migration) compared with CM from
ATMs. More generally, the actions of myofibroblasts are reported
to be both positive and negative on cancer cell proliferation and
migration, and there are also effects on angiogenesis, and
Figure 3. Chemerin increased MIF secretion by MSCs which restrains migratory responses. A, Representative Western blots showing MIF
in MSC media (top left) and cell extracts (bottom left) treated with chemerin (Ch; 100 ng/ml) or IGF-II (100 ng/ml) for 15 min. ChemR23 knock-down
decreased MIF release in response to chemerin (center). Chemerin-stimulated MSC migration was inhibited by MIF (200 ng/ml)(right). B, Suppression
of MIF signaling with ISO-I (50 mM) further increased chemerin-stimulated migration. C, MIF knock-down in MSCs increased migration in response to
4 ng/ml, but not 20 ng/ml chemerin. Horizontal arrows, p,0.05, t- test (n = 3).
doi:10.1371/journal.pone.0104877.g003
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Figure 4. Chemerin stimulates transendothelial migration of MSCs and requires MMP-2. A, Representative fields from MSC
transendothelial migration experiments showing migration of PKH67-labelled MSCs (left). CCX832 (1 mM) inhibited chemerin- (center) and CAM-CM
stimulated MSC transendothelial migration but CCX826 (1 mM) had no effect (right). B, Chemerin, and IGF-II used as a positive control, promptly
(30 min) stimulated proMMP2 abundance in media as detected by Western blot but had no effect on cellular proMMP2 abundance (left); chemerin
Chemerin and MSC Recruitment
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modulation of immune mechanisms [3,12]. However, while MSC
homing to cancer sites is recognised, the specific role of
myofibroblasts in this process has been unclear. The present data
suggest not just that CAMs are active participants in MSC
recruitment but also that one specific mediator, chemerin, is
differentially expressed in CAMs and ATMs.
Chemerin emerged through a proteomic study of myofibroblast
secretomes. There is growing interest in the application of
proteomic studies to define the secretomes of stromal cells, but
even so these remain less well studied than cancer cell secretomes.
Previous secretome studies on both fibroblastic lineage cells and
MSCs have identified some of the molecules found in the present
study notably ECM proteins, MMPs, IGFBPs; signalling mole-
cules identified in these studies include SDF-1, HGF, EGF and
other chemokines [36,37]. Our initial identification of chemerin
was made in all four pairs of cells examined and was validated by
Western blot and ELISA of media which together indicate that
chemerin should be considered a novel mediator of myofibroblast
cell signalling.
Chemerin is normally expressed by adipocytes, liver, lung and
other cells. In a number of cancers, including squamous skin
cancer, melanoma, prostate, lung, breast and hepatocellular
carcinoma, decreased chemerin expression is associated with
adverse outcome. However, it is worth noting that previous work
has not, for the most part, taken account of different patterns of
expression of chemerin in tumor epithelial cells compared with
stromal cells [18,38]. Since chemerin is a chemoattractant for NK
cells and dendritic cells [14,16,19] it has been suggested that loss of
chemerin allows tumors to evade the immune defense mechanisms
that inhibit tumorigenesis [18,38,39]. However, esophageal cells
may provide a tolerogenic environment [40] that mitigates the
protective effects of chemerin. Moreover, in gastric cancer there is
increased plasma chemerin and chemerin stimulates cancer cell
invasion in vitro [41]. Thus, chemerin may exert both positive and
negative effects on tumor progression.
There are multiple potential roles for chemerin released by
CAMs including modulation of cancer and immune cell function
and angiogenesis. We found that the cognate receptor ChemR23
was expressed by MSCs and that chemerin was a chemoattractant
for these cells. Since receptor knockdown, immunoneutralisation
and a ChemR23 receptor antagonist only partially inhibited the
effects of CAM-CM, there are also likely to be other CAM
chemoattractants. We suggest chemerin is a good candidate for
further study not least because of the availability of receptor
antagonists. The mechanisms of chemotaxis include activation of
PKC and of multiple downstream kinase pathways including p42/
44, p38 and JNK-II kinases, all of which seem to play a role. At
least in part these intracellular signalling mechanisms may
resemble those described in other cells that exhibit chemerin-
stimulated chemotaxis including dendritic cells [14].
Previous studies have shown that a variety of growth factors and
chemokines stimulate MSC migration including HGF, TNFa,
SDF-1, CXCL12, CXCL13, CHCL16 and CCL22 [42,43].
MSCs transmigrate across endothelia by chemokine-mediated
mechanisms that also involve matrix metalloproteinases notably
MMP-2 [43,44,45,46,47]. We found rapid (30 min) stimulation of
proMMP-2 secretion by MSCs in response to chemerin and a role
for MMP-2 in facilitating chemerin-stimulated transendothelial
migration, presumably following activation by other extracellular
proteases such as MMP-14 [45].
It is known that MIF inhibits MSC migration [48,49]. The
present data suggest that concentration-dependent induction of
significantly increased MMP-2 enzyme activity in MSC media detected by the selective substrate MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2 (right). C,
Human recombinant MMP-2 (80 ng/ml) stimulated transendothelial migration and there was dose-dependent inhibition by an MMP-2 selective
inhibitor (MMP-2 inhibitor I) (left). The MMP-2 inhibitor (60 mM) significantly inhibited chemerin-stimulated MSC transendothelial migration (centre).
Horizontal arrows, p,0.05, t- test (n = 3).
doi:10.1371/journal.pone.0104877.g004
Figure 5. Increased MSC homing to xenografts seeded with CAMs and inhibition of homing by the chemR23 receptor antagonist,
CCX832. A, Visualisation of PKH67-labelled MSCs in representative fields from xenografts established with OE21 cancer cells alone or co-injected
with CAMs followed by treatment with vehicle (top) or CCX832 (bottom) and iv injection of PKH67-labelled MSCs. B, In xenografts with OE21 cancer
cells and CAMs there was increased MSC homing expressed as labelled cells per unit area of xenograft compared with xenografts of OE21 cancer cell
alone; treatment with CCX832 inhibited homing (OE21/vehicle, n = 3; OE21/CCX832, n = 4; OE21 and CAMs/vehicle, n = 6; OE21 and CAMs/CCX832,
n = 6). Horizontal arrows, p,0.05, ANOVA.
doi:10.1371/journal.pone.0104877.g005
Chemerin and MSC Recruitment
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MIF in MSCs by chemerin acts to restrain migration. However,
the inhibitory effect is attenuated at high concentrations of
chemerin. One implication is that control myofibroblasts, where
chemerin expression is modest, do not effectively promote MSC
recruitment because of the autoinhibitory action of MIF; however
in CAMs where there is increased chemerin, the capacity for MSC
recruitment is enhanced since the autoinhibitory effect of MIF is
overcome.
The ChemR23 antagonist CCX832 has previously been used to
define novel interactions between perivascular adipocytes and
vasoconstrictor responses [26]. We now show both in vitro and in
vivo in a xenograft model that CCX832 inhibits MSC migration
in response to CAMs. Whether chemerin influences MSC
differentiation after recruitment to cancers remains to be
determined. It would not be surprising if it did, since it is known
to stimulate mesenchymal stem cell adipogenesis [17,50]. Taken as
a whole the present data indicate chemerin is a novel potential
regulator of cancer progression by targeting MSC recruitment and
suggest the feasibility of using ChemR23 receptor antagonists to
regulate this process.
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